Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-29, Stock:LLY, The news for the past five days is as follows:
2019-07-22: NEWS1: The Implied Analyst 12-Month Target For EQWL.NEWS2: The Implied Analyst 12-Month Target For EQWL.
2019-07-23: NEWS1: Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline.NEWS2: Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline.NEWS3: Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline.
2019-07-24: NEWS1: Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?.NEWS2: Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?.NEWS3: Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?.
2019-07-25: NEWS1: Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?.NEWS2: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug.NEWS3: UPDATE 1-Eli Lilly's hypoglycemia treatment wins FDA approval.NEWS4: BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA.
2019-07-26: NEWS1: Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment.NEWS2: Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment.NEWS3: Senate advances bill to cut the cost of prescriptions.NEWS4: EMA panel recommends approving Bayer's cancer drug Vitrakvi.NEWS5: Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?.NEWS6: Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?.

Answer: Rise